Recent advances in multifunctional dendrimer-based nanoprobes for breast cancer theranostics

Kesharwani, Prashant; Chadar, Rahul; Shukla, Rahul; Jain, Gaurav; Aggarwal, Geeta; Abourehab, Mohammad A. S.; Sahebkar, Amirhossein

doi:10.1080/09205063.2022.2103627

Cited by 16 publications

(5 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dendritic nanoparticle is composed of three parts, a central core, repeating branching units and outer surface functional group, with a size ranging from 1-100 nm (Kesharwani et al, 2022). Dendrimers are especially helpful for improving the solubility of hydrophobic drugs, because the core of dendrimers is usually hydrophobic (Saravanakumar et al, 2022).…”

Section: Dendrimersmentioning

confidence: 99%

“…Besides, the outer surface functional group can be extensively chemically modified or complexed with drugs, targeting ligands, as well as imaging agents (Kim et al, 2018). The dendrimers widely used in cancer treatment include poly (L-lysine) (PLL) dendrimers, polypropylene imine (PPI) dendrimers, polyamidoamine (PAMAM) dendrimers, and PAMAM-organosilicon dendrimers (PAMAMOS) (Kesharwani et al, 2022). Therefore, these diversified characteristics and properties make dendrimers a good platform for drugs delivery in the treatment of cancers.…”

Section: Dendrimersmentioning

confidence: 99%

See 1 more Smart Citation

The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies

Yang

Dai

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequently diagnosed malignant tumor among women in the world. BC is the heterogeneous tumor with different subtypes including luminal A-like, luminal B-like (HER2-/HER2+), HER2 enriched, and triple-negative BC. The therapeutic strategies including surgery, chemotherapy, radiotherapy, targeted therapy, and endocrine therapy are well developed and commonly used in the treatment of BC. However, some adverse effects of these conventional treatments limited their wide application in clinical. Therefore, it is necessary to develop more safe and more efficient individualized treatment strategies of the BC. Nanomedicine, as the most promising strategy for controlled and targeted drug delivery, is widely used in multiple aspects of cancer therapy. Importantly, accumulative evidences show that nanomedicine has achieved good outcomes in the treatment of BC and a huge amount of BC patients benefited from the nanomedicine related treatments. In this review, we summarized and discussed the major problems occurred during the administration of conventional treatment strategies for BC and the potential roles of nanomedicine in promoting the treatment efficacy of BC by overcoming obstacles of current treatment of BC.

show abstract

Section: Dendrimersmentioning

confidence: 99%

Section: Dendrimersmentioning

confidence: 99%

The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies

Yang

Dai

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Dendrimers are tree-like, multi-branched, low-molecular-weight polymeric nano-carriers consisting of a core and inner and outer shells [ 139 – 146 ]. The inner shell is composed of numerous repeating layers of monomeric units (known as generations) created by chemical reactions, while the outer shell consists of several functional groups that determine the dendrimer’s properties [ 144 , 146 – 151 ]. Polyamidoamine (PAMAM) dendrimers are among the most extensively researched dendrimers for gene delivery applications.…”

Section: A Cocktail Of Aptamer/sirna Mediated Chemotherapy Against Pa...mentioning

confidence: 99%

Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer

et al. 2023

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor prognosis can be attributed to both troublesome detections at the initial stage, which makes the majority of the treatment options largely unsuccessful and leads to extensive metastasis, as well as to its distinct pathophysiological characteristics, such as rich desmoplastic tumours bounded by dysplastic and hypo perfused vessels restricting the mobility of therapeutic agents. Continued attempts have been made to utilise innovative measures for battling PC to increase the therapeutic effectiveness of therapies and overcome their cytotoxicity. Combined cancer targeting and gene silencing approach has shown improved outcomes in patients’ survival rates and quality of life, offering a potential solution to therapeutic complications. It particularly targets various barriers to alleviate delivery problems and diminish tumour recurrence and metastasis. While aptamers, a type of single-stranded nucleic acids with strong binding affinity and specificity to target molecules, have recently surfaced as a viable PC strategy, siRNA can interfere with the expression of certain genes. By concurrently suppressing genes and boosting targeted approach, the cocktail of siRNA/Aptamer and other therapeutic drugs can circumvent the multi-drug resistance phenomena. Additionally, combination therapy with additive or synergistic effects can considerably increase the therapeutic efficacy of anti-cancer medications. This study outlines the primary difficulties in treating PC, along with recent developments in siRNA/Aptamer mediated drug delivery to solve the major hiccup of oncology field. Graphical Abstract

show abstract

“…Dendrimers are monodisperse polymers with a highly branched structure consisting of an inner core, a polymer backbone and side chains of dendritic units ( Sherje et al, 2018 ; Kesharwani et al, 2022 ). The most important feature of the dendritic macromolecule is its built-in cavity structure, which protects DOX from enzymatic digestion and hydrolysis and reduces rapid clearance by the immune system.…”

Section: Novel Nano-drug Delivery Systemsmentioning

confidence: 99%

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer

Zeng,

Luo,

Gan

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer. Due to the unique cell phenotype, aggressiveness, metastatic potential and lack of receptors or targets, chemotherapy is the choice of treatment for TNBC. Doxorubicin (DOX), one of the representative agents of anthracycline chemotherapy, has better efficacy in patients with metastatic TNBC (mTNBC). DOX in anthracycline-based chemotherapy regimens have higher response rates. Nano-drug delivery systems possess unique targeting and ability of co-load, deliver and release chemotherapeutic drugs, active gene fragments and immune enhancing factors to effectively inhibit or kill tumor cells. Therefore, advances in nano-drug delivery systems for DOX therapy have attracted a considerable amount of attention from researchers. In this article, we have reviewed the progress of nano-drug delivery systems (e.g., Nanoparticles, Liposomes, Micelles, Nanogels, Dendrimers, Exosomes, etc.) applied to DOX in the treatment of TNBC. We also summarize the current progress of clinical trials of DOX combined with immune checkpoint inhibitors (ICIS) for the treatment of TNBC. The merits, demerits and future development of nanomedicine delivery systems in the treatment of TNBC are also envisioned, with the aim of providing a new class of safe and efficient thoughts for the treatment of TNBC.

show abstract

Recent advances in multifunctional dendrimer-based nanoprobes for breast cancer theranostics

Cited by 16 publications

References 210 publications

The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies

The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies

Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer

Contact Info

Product

Resources

About